Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group.
cosmeceutical
cosmetic dermatology
facial redness
rosacea
skin care
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
03
06
2020
revised:
22
06
2020
accepted:
29
06
2020
pubmed:
6
7
2020
medline:
15
5
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
Rosacea is a common inflammatory skin disorder with centrofacial erythema, flushing, telangiectasia, papules/pustules, and possible ocular or phymatous manifestation. Patients' skin is particularly sensitive to chemical and physical stimuli leading to burning, stinging, dryness, and skin tightness. Dermatological evaluation of the efficacy and safety of skin care products designed for centrofacial erythema in rosacea patients, in comparison with a control group using objective measurements. Rosacea symptoms (itching, tension, warmth, burning, dryness) and quality of life were examined. Sixty Caucasians with centrofacial erythema were enrolled in an 8-week prospective study, fifty of them exclusively using the study products (micellar water, cream, and serum) with ten participants randomly assigned to a control group. Patients were evaluated at baseline (V0), at 4 weeks (V1), and at 8 weeks (V2). Three-dimensional objective measurements (VECTRA Results were compared with the control group. A significant reduction of 16% in skin redness as indicated by VECTRA A skin care regime suitable for sensitive and redness-prone skin led to an enhanced clinical appearance, to a decrease of associated symptoms in rosacea patients, and to an improved life quality.
Sections du résumé
BACKGROUND
BACKGROUND
Rosacea is a common inflammatory skin disorder with centrofacial erythema, flushing, telangiectasia, papules/pustules, and possible ocular or phymatous manifestation. Patients' skin is particularly sensitive to chemical and physical stimuli leading to burning, stinging, dryness, and skin tightness.
OBJECTIVE
OBJECTIVE
Dermatological evaluation of the efficacy and safety of skin care products designed for centrofacial erythema in rosacea patients, in comparison with a control group using objective measurements. Rosacea symptoms (itching, tension, warmth, burning, dryness) and quality of life were examined.
METHODS
METHODS
Sixty Caucasians with centrofacial erythema were enrolled in an 8-week prospective study, fifty of them exclusively using the study products (micellar water, cream, and serum) with ten participants randomly assigned to a control group. Patients were evaluated at baseline (V0), at 4 weeks (V1), and at 8 weeks (V2). Three-dimensional objective measurements (VECTRA
RESULTS
RESULTS
Results were compared with the control group. A significant reduction of 16% in skin redness as indicated by VECTRA
CONCLUSIONS
CONCLUSIONS
A skin care regime suitable for sensitive and redness-prone skin led to an enhanced clinical appearance, to a decrease of associated symptoms in rosacea patients, and to an improved life quality.
Substances chimiques
Micelles
0
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2627-2633Subventions
Organisme : LETI Pharma GmbH
Informations de copyright
© 2020 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65-79.
Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the national rosacea society expert committee. J Am Acad Dermatol. 2020;82(6):1501-1510.
Tan J, Schöfer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M. Prevalence of rosacea in the general population of Germany and Russia - The RISE study. J Eur Acad Dermatol Venereol. 2016;30:428-434.
Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269-1276.
Tan J, Berg M, Gallo RL, Del Rosso JQ. Applying the phenotype approach for rosacea to practice and research. Br J Dermatol. 2018;179:741-746.
Reinholz M, Ruzicka T, Steinhoff M, et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Ges. 2016;14(Suppl 6):4-15.
Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71:973-980.
Hoepfner A, Marsela E, Clanner-Engelshofen BM, et al. Rosacea and perioral dermatitis: a single-center retrospective analysis of the clinical presentation of 1032 patients. J Dtsch Dermatol Ges. 2020;18:561-570.
Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151:1213-1219.
Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135:1548-1555.
Clanner-Engelshofen BM, French LE, Reinholz M. Corynebacterium kroppenstedtii subsp. demodicis is the endobacterium of Demodex folliculorum. J Eur Acad Dermatol Venereol. 2020;34(5):1043-1049.
Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17(9):1562.
Reinholz M, Tietze JK, Kilian K, et al. Rosacea - S1 guideline. J Dtsch Dermatol Ges. 2013;11(768-780):768-779.
Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24:126-135.
Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
Ni Raghallaigh S, Powell FC. Epidermal hydration levels in patients with rosacea improve after minocycline therapy. Br J Dermatol. 2014;171:259-266.
Misery L, Loser K, Stander S. Sensitive skin. J Eur Acad Dermatol Venereol. 2016;30(Suppl 1):2-8.
Kresken J, Kindl U, Wigger-Alberti W, Clanner-Engelshofen BM, Reinholz M. Dermocosmetics for use in rosacea: guideline of the society for dermopharmacy. Skin Pharmacol Physiol. 2018;31:147-154.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
Guertler A, Reinholz M, Steckmeier S, Gauglitz GG. Evaluation of a non-ablative, fractional 1565 nm laser for the improvement of striae distensae albae. J Eur Acad Dermatol Venereol. 2019;33:220-226.
Oussedik E, Bourcier M, Tan J. Psychosocial burden and other impacts of rosacea on patients' quality of life. Dermatol Clin. 2018;36:103-113.
Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. 2020;31:168-174.
Fan L, Jia Y, Cui L, Li X, He C. Analysis of sensitive skin barrier function: basic indicators and sebum composition. Int J Cosmet Sci. 2018;40:117-126.
Draelos ZD. Cosmeceuticals for rosacea. Clin Dermatol. 2017;35:213-217.
Dupont E, Léveillé C, Gomez J, Loigeret M, Loing E, Bilodeau D. Clinical efficacy of a serum integrating multiple cosmetic ingredients in the management of erythema of the face in aging skin. J Cosmet Dermatol. 2012;11:207-212.